The Role of GLP1 Receptor Agonists and Multi-agonist Incretin Therapies for Specific Obesity-related Health Conditions: Evidence and Rationale for Prioritisation.

Curr Obes Rep · 2026

Last updated 2026-05-28

Journal	Curr Obes Rep, 2026
Citations	0
Molecules	—
Conditions studied	Obesity, Cardiovascular Risk Reduction, Chronic Kidney Disease, Mash, Obstructive Sleep Apnea, Pcos, Heart Failure

Full record and abstract on PubMed 41922811 ↗